Stockscreener 앱 받기
0.00
100.00%
-27.73
Galapagos Nv Adr 주식(GLPG)의 최신 뉴스
Why Is Galapagos N.V. Sponsored ADR (LKFT) Stock Up Today? - Meyka
Why Is Galapagos N.V. Sponsored ADR (LKFT) Stock Down Today? - Meyka
Galapagos N.V. Sponsored ADR (LKFT) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
LKFT Stock Price, Quote & Chart | LAKEFRONT BIOTHERAPEUTIC-ADR (NASDAQ:LKFT) - ChartMill
GLPG SEC FilingsGalapagos Nv 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 - Investing.com
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 By Investing.com - Investing.com South Africa
Galapagos NV Sponsored ADR (LKFT) Stock Live Price, Chart & News - CoinCodex
Lakefront Biotherapeutics (NASDAQ: GLPG) outlines ADR deposit terms - Stock Titan
LKFT Stock Price and Chart — NASDAQ:LKFT - TradingView
LKFT Stock Price and Chart — EURONEXT:LKFT - TradingView
Galapagos Q1 2026 presentation: Ouro deal, rebranding highlight transformation By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q1 2026 beats EPS, revenue falls short By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q1 2026 beats EPS, revenue falls short - Investing.com
Galapagos Q1 2026 presentation: Ouro deal, rebranding highlight transformation - Investing.com
Galapagos (GLPG) posts Q1 2026 profit and commits up to €790M to Ouro deal - Stock Titan
GLPG.AS Stock Price, Quote & Chart | GALAPAGOS NV (AMS:GLPG) - ChartMill
GLPG Stock Price, Quote & Chart | GALAPAGOS NV-SPON ADR (NASDAQ:GLPG) - ChartMill
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Benzinga
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Sahm
ETFs Investing in Galapagos NV Sponsored ADR Stocks - TradingView
Galapagos FY 2025 slides: €3B cash fuels transformation strategy - Investing.com Australia
RBC Capital raises Galapagos stock price target to $33 on model updates - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises By Investing.com - Investing.com South Africa
Galapagos stock rating reiterated at Market Perform by Raymond James - Investing.com
Galapagos FY 2025 slides: €3B cash fuels transformation strategy By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises - Investing.com
Earnings Breakdown: Galapagos Q4 - Sahm
A Peek at Galapagos's Future Earnings - Sahm
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones Futures Drop After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus - Sahm
AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Galapagos stock holds steady as Raymond James maintains Market Perform rating - Investing.com
Bernstein initiates Market Perform rating on Galapagos stock with EUR27.90 target - Investing.com
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady - Investing.com
Galapagos stock price target raised to $28 from $27 at RBC Capital - Investing.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks - Benzinga
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN) - The Globe and Mail
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - TechStock²
Galapagos NV (GLPG)' CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial - Finviz
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
GLPG Stock Price, News & Analysis - Stock Titan
Galapagos To Spin Off Innovative Medicines Business - Forbes
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com UK
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
ProShares Ultra Nasdaq Biotechnology Holdings - Quiver Quantitative
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
What is the current Price Target and Forecast for Galapagos (GLPG) - Zacks Investment Research
BeiGene Ltd. (BGNE) Share Price, Stock Analysis, Annual Report - Value Research
GLPG Stock Price and Chart — EURONEXT:GLPG - TradingView
These stocks are gapping in today's session - ChartMill
Which stocks are moving after the closing bell on Wednesday? - ChartMill
Which stocks are moving before the opening bell on Thursday? - ChartMill
Galapagos Gets First Commercial Drug With Jyseleca Approval - Yahoo Finance
3.86%
자본화:
|
볼륨(24시간):